JP2016511267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511267A5 JP2016511267A5 JP2015560714A JP2015560714A JP2016511267A5 JP 2016511267 A5 JP2016511267 A5 JP 2016511267A5 JP 2015560714 A JP2015560714 A JP 2015560714A JP 2015560714 A JP2015560714 A JP 2015560714A JP 2016511267 A5 JP2016511267 A5 JP 2016511267A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- contact activation
- surgery
- reperfusion
- iri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 24
- 230000004913 activation Effects 0.000 claims 22
- 206010063837 Reperfusion injury Diseases 0.000 claims 12
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 11
- 238000011477 surgical intervention Methods 0.000 claims 8
- 238000001356 surgical procedure Methods 0.000 claims 6
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000010410 reperfusion Effects 0.000 claims 5
- 102100027637 Plasma protease C1 inhibitor Human genes 0.000 claims 4
- 108050007539 Plasma protease C1 inhibitor Proteins 0.000 claims 4
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 claims 2
- 101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 claims 2
- 229940122920 Kallikrein inhibitor Drugs 0.000 claims 2
- 102100023012 Kallistatin Human genes 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000002537 thrombolytic effect Effects 0.000 claims 2
- 229940124549 vasodilator Drugs 0.000 claims 2
- 239000003071 vasodilator agent Substances 0.000 claims 2
- 208000025962 Crush injury Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000002283 elective surgery Methods 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000002324 minimally invasive surgery Methods 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019170986A JP7666891B2 (ja) | 2013-03-08 | 2019-09-20 | 遠隔虚血再灌流傷害の治療および予防 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13158478 | 2013-03-08 | ||
| EP13158478.1 | 2013-03-08 | ||
| PCT/EP2014/054489 WO2014135694A1 (en) | 2013-03-08 | 2014-03-07 | Treatment and prevention of remote ischemia-reperfusion injury |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019170986A Division JP7666891B2 (ja) | 2013-03-08 | 2019-09-20 | 遠隔虚血再灌流傷害の治療および予防 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511267A JP2016511267A (ja) | 2016-04-14 |
| JP2016511267A5 true JP2016511267A5 (enExample) | 2017-03-23 |
| JP6636334B2 JP6636334B2 (ja) | 2020-01-29 |
Family
ID=47833003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560714A Active JP6636334B2 (ja) | 2013-03-08 | 2014-03-07 | 遠隔虚血再灌流傷害の治療および予防 |
| JP2019170986A Active JP7666891B2 (ja) | 2013-03-08 | 2019-09-20 | 遠隔虚血再灌流傷害の治療および予防 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019170986A Active JP7666891B2 (ja) | 2013-03-08 | 2019-09-20 | 遠隔虚血再灌流傷害の治療および予防 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10286047B2 (enExample) |
| EP (1) | EP2964255B1 (enExample) |
| JP (2) | JP6636334B2 (enExample) |
| KR (1) | KR102403299B1 (enExample) |
| CN (1) | CN105188750A (enExample) |
| AU (1) | AU2014224599B2 (enExample) |
| CA (1) | CA2901225C (enExample) |
| DK (1) | DK2964255T3 (enExample) |
| ES (1) | ES2844189T3 (enExample) |
| WO (1) | WO2014135694A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2683397T3 (en) | 2011-03-09 | 2017-09-18 | Csl Behring Gmbh | FACTOR XII INHIBITORS FOR ADMINISTRATION OF MEDICAL PROCEDURES COMPREHENSIVE CONTACT WITH ARTIFICIAL SURFACES |
| WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| KR102403299B1 (ko) | 2013-03-08 | 2022-06-03 | 체에스엘 베링 게엠베하 | 원격 허혈-재관류 손상의 치료 및 예방 |
| ES2708655T3 (es) * | 2013-11-22 | 2019-04-10 | Shire Viropharma Inc | Métodos para tratar el rechazo mediado por anticuerpos en pacientes con trasplante de órganos con el inhibidor de la c1-esterasa |
| CN106456778A (zh) | 2014-06-18 | 2017-02-22 | 德国杰特贝林生物制品有限公司 | 在神经创伤性病患中使用因子xii抑制剂进行治疗 |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| WO2017087882A1 (en) * | 2015-11-19 | 2017-05-26 | Shire Human Genetic Therapies, Inc. | Recombinant human c1 esterase inhibitor and uses thereof |
| AU2017247004B2 (en) * | 2016-04-06 | 2022-07-07 | Csl Limited | Method of treating atherosclerosis |
| US20190175683A1 (en) | 2016-08-05 | 2019-06-13 | Csl Behring Gmbh | Pharmaceutical formulations of c1 esterase inhibitor |
| CN116622006B (zh) | 2017-03-10 | 2025-05-30 | 北卡罗来纳大学查珀尔希尔分校 | 短效的基于肝素的抗凝血剂化合物和方法 |
| WO2019010216A1 (en) | 2017-07-03 | 2019-01-10 | The University Of North Carolina At Chapel Hill | ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES |
| US11865137B2 (en) | 2017-11-03 | 2024-01-09 | The University Of North Carolina At Chapel Hill | Sulfated oligosaccharides having anti-inflammatory activity |
| AU2018382222B2 (en) * | 2017-12-15 | 2025-09-04 | Csl Limited | Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
| US11633424B2 (en) | 2018-06-20 | 2023-04-25 | The University Of North Carolina At Chapel Hill | Cell protective methods and compositions |
| CN108852308B (zh) * | 2018-06-22 | 2021-03-30 | 苏州高新区人民医院 | 一种基于多参数影像技术优化检测体系的超时间窗ais临床再灌注方法 |
| WO2020210491A1 (en) * | 2019-04-10 | 2020-10-15 | Pantheryx, Inc. | Methods and compositions for reducing gut ischemia/reperfusion-induced injury |
| CN114072425A (zh) * | 2019-06-12 | 2022-02-18 | 杰特创新股份有限公司 | 可溶性补体受体1型变体缀合物及其用途 |
| CN114980904A (zh) | 2019-11-13 | 2022-08-30 | 北卡罗来纳大学查珀尔希尔分校 | 硫酸乙酰肝素(hs)低聚糖在肝缺血再灌注损伤中的影响 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5714358A (en) | 1980-07-02 | 1982-01-25 | Toray Industries | Antithrombus medical material |
| US4383219A (en) | 1980-08-19 | 1983-05-10 | Indiana University Foundation | Nuclear magnetic resonance spatial mapping |
| DE3228502A1 (de) | 1982-07-30 | 1984-02-02 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung des c1-inaktivators und seine verwendung |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| EP0534988A1 (en) | 1990-05-10 | 1993-04-07 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
| DE4222534A1 (de) | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
| DE4244735A1 (de) | 1992-08-24 | 1994-03-31 | Behringwerke Ag | Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen |
| US5380299A (en) | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
| DE69429816T2 (de) * | 1993-09-01 | 2002-09-19 | Stichting Sanquin Bloedvoorziening, Amsterdam | C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt |
| EP1621206A1 (en) | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
| US5786692A (en) | 1995-08-18 | 1998-07-28 | Brigham And Women's Hospital, Inc. | Line scan diffusion imaging |
| DE19903693A1 (de) | 1998-04-24 | 1999-10-28 | Centeon Pharma Gmbh | Protease zur Aktivierung des Gerinnungsfaktors VII |
| US5674236A (en) | 1996-04-30 | 1997-10-07 | Medtronic, Inc. | Lancet for capillary puncture blood samples |
| JPH11209399A (ja) | 1997-11-20 | 1999-08-03 | Asahi Chem Ind Co Ltd | 高比重リポ蛋白質を有効成分とする医薬組成物 |
| US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| GB9800817D0 (en) | 1998-01-16 | 1998-03-11 | Bio Discovery Ltd | Serine protease inhibitors |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU6083899A (en) | 1999-09-16 | 2001-04-17 | Aventis Behring Gmbh | Combination of c1-inh and lung surfactant for the treatment of respiratory disorders |
| JP2001276217A (ja) | 2000-04-04 | 2001-10-09 | Dountsuendorufaa Udo | 単一又は複数の疾患のある患者での組織、血漿又は血液透析用のバイオコートされた吸着剤 |
| EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| DK1435877T3 (da) | 2001-10-15 | 2009-08-03 | Hemoteq Ag | Overtrækning af stents for at forhindre restenose |
| IL162803A0 (en) | 2002-02-06 | 2005-11-20 | Orbus Medical Technologies Inc | Medical device with coating that promotes endothelial cell adherence and differentiation |
| CA2475761C (en) | 2002-02-11 | 2011-07-12 | Gold-T Tech, Inc. | An implantable device which provides high frequency ultrasound energy to provide acoustical streaming to prevent thrombus formation |
| IL163586A0 (en) | 2002-02-21 | 2005-12-18 | Quark Biotech Inc | Methods of preventing or treating brain ischemia or brain injury |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| WO2004057343A2 (en) | 2002-12-20 | 2004-07-08 | Axis-Shield Diagnostics Limited | Detection or determination of variants of factor xiia |
| DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
| EP1601377A4 (en) | 2003-02-21 | 2009-07-15 | Genentech Inc | METHOD FOR THE PREVENTION AND TREATMENT OF TISSUE DAMAGE IN CONNECTION WITH ISCHEMIC REPERFUSION DAMAGE |
| US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| ES2333598T5 (es) | 2003-05-06 | 2013-09-04 | Biogen Idec Hemophilia Inc | Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia. |
| PT1626736T (pt) | 2003-05-16 | 2020-10-13 | Pharming Intellectual Property B V | Inibidor c1 com curta meia-vida para tratamento transitório |
| JP4629047B2 (ja) | 2003-06-12 | 2011-02-09 | イーライ リリー アンド カンパニー | Ｇｌｐ−１アナログ複合タンパク質 |
| US20050059660A1 (en) | 2003-08-01 | 2005-03-17 | Pharmacia & Upjohn Company | Novel combination |
| US7550263B2 (en) | 2003-09-05 | 2009-06-23 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| BRPI0417916A (pt) | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| CA2580981C (en) | 2004-09-22 | 2013-10-22 | Kirin Beer Kabushiki Kaisha | Stabilized human igg4 antibodies |
| US7235530B2 (en) * | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| ES2407965T3 (es) | 2004-12-23 | 2013-06-17 | Csl Behring Gmbh | Prevención de la formación y/o estabilización de trombos |
| SI2380587T1 (en) | 2005-12-21 | 2018-03-30 | Pharming Intellectual Property B.V. | Use of a C1 inhibitor to prevent ischemic reperfusion injury |
| US20070196367A1 (en) | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
| EP2004139A1 (en) | 2006-03-31 | 2008-12-24 | Adenobio N.V. | Compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment |
| GB0607515D0 (en) | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| SI3028716T1 (sl) | 2006-10-10 | 2021-01-29 | Regenesance B.V. | Komplementarna inhibicija za izboljšano regeneracijo živcev |
| PE20081834A1 (es) | 2006-12-31 | 2009-01-16 | Boehringer Ingelheim Int | Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos |
| US20100119512A1 (en) | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
| EP2109457B1 (en) | 2007-02-12 | 2016-01-06 | CSL Behring GmbH | Therapeutic application of kazal-type serine protease inhibitors |
| ES2566963T3 (es) | 2007-11-21 | 2016-04-18 | Oregon Health & Science University | Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos |
| WO2010049423A1 (en) | 2008-10-27 | 2010-05-06 | Life Sciences Research Partners Vzw | Effects of nitric oxide inhalation on long-term myocardial reperfusion injury |
| US20100143325A1 (en) | 2008-12-09 | 2010-06-10 | Vascular Laboratory, Inc. | Composition And Methods Involving Thrombolytic Agents |
| ES2733067T3 (es) | 2008-12-19 | 2019-11-27 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| BRPI1006998A2 (pt) | 2009-01-23 | 2015-08-25 | Biogen Idec Inc | Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso |
| MY157239A (en) | 2009-05-27 | 2016-05-13 | Baxalta Inc | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
| EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| DK2683397T3 (en) * | 2011-03-09 | 2017-09-18 | Csl Behring Gmbh | FACTOR XII INHIBITORS FOR ADMINISTRATION OF MEDICAL PROCEDURES COMPREHENSIVE CONTACT WITH ARTIFICIAL SURFACES |
| JP6253578B2 (ja) | 2011-07-22 | 2017-12-27 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用 |
| AU2012311483B2 (en) * | 2011-09-24 | 2016-03-10 | Csl Behring Gmbh | Combination therapy using immunoglobulin and C1-inhibitor |
| EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| HUE044285T2 (hu) * | 2013-01-20 | 2019-10-28 | Dyax Corp | PKal-mediálta rendellenességek értékelése, vizsgálata és kezelése |
| KR102403299B1 (ko) | 2013-03-08 | 2022-06-03 | 체에스엘 베링 게엠베하 | 원격 허혈-재관류 손상의 치료 및 예방 |
| JP2017501968A (ja) | 2013-06-28 | 2017-01-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法 |
| AU2017247004B2 (en) | 2016-04-06 | 2022-07-07 | Csl Limited | Method of treating atherosclerosis |
-
2014
- 2014-03-07 KR KR1020157028040A patent/KR102403299B1/ko active Active
- 2014-03-07 DK DK14708308.3T patent/DK2964255T3/da active
- 2014-03-07 US US14/773,020 patent/US10286047B2/en active Active
- 2014-03-07 AU AU2014224599A patent/AU2014224599B2/en active Active
- 2014-03-07 CN CN201480012556.0A patent/CN105188750A/zh active Pending
- 2014-03-07 CA CA2901225A patent/CA2901225C/en active Active
- 2014-03-07 EP EP14708308.3A patent/EP2964255B1/en active Active
- 2014-03-07 WO PCT/EP2014/054489 patent/WO2014135694A1/en not_active Ceased
- 2014-03-07 JP JP2015560714A patent/JP6636334B2/ja active Active
- 2014-03-07 ES ES14708308T patent/ES2844189T3/es active Active
-
2019
- 2019-03-20 US US16/359,598 patent/US10973891B2/en active Active
- 2019-09-20 JP JP2019170986A patent/JP7666891B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505761A5 (enExample) | ||
| JP2020524689A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| PH12013500215B1 (en) | Corticosteroids for the treatment of joint pain | |
| EP4483955A3 (en) | Methods of medical treatment with sur1-trpm4 channel inhibitors | |
| JP2015502389A5 (enExample) | ||
| HK1255584A1 (zh) | 使用阿坎酸及d-环丝胺酸的联合疗法 | |
| MX2022011214A (es) | Composiciones y metodos para el tratamiento de lesion por reperfusion o hemorragia despues de la terapia de recanalizacion. | |
| CN105497020A (zh) | 胺类化合物的光学异构体治疗疼痛的医药用途 | |
| JP2014534229A5 (enExample) | ||
| MX336278B (es) | Composiciones y metodos para la prevencion y el tratamiento de heridas. | |
| WO2014100679A8 (en) | Stimulation and enhancement of regeneration of tissues | |
| CN105497019A (zh) | 胺类化合物治疗疼痛的医药用途 | |
| JP2010519192A5 (enExample) | ||
| EA201792565A1 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
| MX2007010886A (es) | Metodos y formulaciones de acarbosa para tratar constipacion cronica. | |
| RU2010140888A (ru) | Улучшенные противораковые терапии | |
| WO2024178350A1 (en) | Methods of treating sepsis using poly(lactic acid) nanoparticles | |
| Choi et al. | The effect of tamsulosin and nifedipine on expulsion of ureteral stones after extracorporeal shock wave lithotripsy | |
| Metaxas et al. | Rib fractures and nerve block | |
| HE et al. | Treatment of gastroesophageal varices of Le, g type with endoscopic tissue adhesive injection combined with sequential endoscopic variceal ligation | |
| JP2019533018A5 (enExample) | ||
| Fang et al. | Intravesical drug delivery into the bladder to treat cancers | |
| Metaxas et al. | Rib fractures and nerve block: A 63 case study | |
| Srivastava et al. | Effectiveness of alpha blockers+ corticosteroids in expulsion of ureteric stones: a clinical observation |